A Controlled Study of Vitamin D3 to Prevent Bone Loss in Renal-Transplant Patients Receiving Low Doses of Steroids
| Autor: | Daniel Abramowicz, K. Martin Wissing, Rodrigo Moreno-Reyes, Bernard Stallenberg, Nilufer Broeders, Christine Gervy |
|---|---|
| Přispěvatelé: | Clinical sciences |
| Rok vydání: | 2005 |
| Předmět: |
Adult
Graft Rejection Male medicine.medical_specialty Bone density Prednisolone Osteoporosis Population Urology Parathyroid hormone chemistry.chemical_compound Bone Density Risk Factors Internal medicine Journal Article medicine Vitamin D and neurology Humans Prospective Studies education Aged Cholecalciferol Bone mineral Transplantation education.field_of_study business.industry clinical trial Middle Aged medicine.disease Kidney Transplantation Endocrinology chemistry Parathyroid Hormone Randomized Controlled Trial Calcium Female business |
| Zdroj: | Transplantation. 79:108-115 |
| ISSN: | 0041-1337 |
| DOI: | 10.1097/01.tp.0000149322.70295.a5 |
| Popis: | BACKGROUND: New and potent immunosuppressive regimens allow for reduced doses of corticosteroids after renal transplantation. The aims of our study were to investigate whether the use of low-dose corticosteroids is associated with a reduction in posttransplant bone loss and to assess the ability of cholecalciferol supplementation to further decrease bone loss in this setting. METHODS: Ninety patients admitted for renal transplantation and scheduled to be treated per protocol with low doses of prednisolone were randomized to receive either 400 mg daily oral calcium (Ca group, n=44) or the same dose of calcium in association with a monthly dose of 25,000 IU of vitamin D3 (CaVitD group, n=46). Bone mineral density (BMD) was measured by dual energy absorptiometry at baseline and at 1 year. RESULTS: The overall population experienced a moderate but significant -2.3+/-0.9% loss of lumbar spine BMD (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|